Publications Database

Aman M. G. et al. (2014)

A review of atomoxetine effects in young people with developmental disabilities.

Research in Developmental Disabilities

June, 35(6), pp. 1412-1424.

Read Full (New Window)

Aman M. G. et al. (2005)

Acute and long-term safety and tolerability of risperidone in children with autism.

Journal of Child and Adolescent Psychopharmacology

15(6), pp. 869-884

Read Abstract (New Window)

Aman M. G. et al. (2015)

Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial.

Journal of Child and Adolescent Psychopharmacology

August, 25(6), pp. 482-493.

Read Abstract (New Window) Read Full (New Window)

Anderson G. M. et al. (2007)

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

February, 61(4), pp. 545-550.

Read Abstract (New Window)

Armenteros J. et al. (1995)

Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children.

Psychopharmacology Bulletin

31(2), pp. 363-369

Read Abstract (New Window)

Banov C. (1979)

Risks with controlling diet.

Journal of Autism and Developmental Disorders

9(1), pp. 135-136

Read Extract (New Window)

Baxter A. , Krenzelok E. (2008)

Pediatric fatality secondary to EDTA chelation.

Clin Toxicol (Phila).

46(10), pp. 1083-1084

Read Abstract (New Window) Read Full (New Window)

Benjamin S. et al. (1995)

Case study: paradoxical response to naltrexone treatment of self-injurious behavior.

Journal of the American Academy of Child and Adolescent Psychiatry

34(2), pp. 238-242

Read Abstract (New Window)

Boyd K. , Woodbury-Smith M. R. , Szatmari P. (2011)

Managing anxiety and depressive symptoms in adults with autism-spectrum disorders.

Journal of Psychiatry and Neuroscience

36(4), E 35-36

Read Full (New Window)

Boyd C. , Moodambail A. (2016)

Severe hypercalcaemia in a child secondary to use of alternative therapies

BMJ Case Reports

Read Abstract (New Window)

Brasić J. R. (1997)

Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid.

Psychology Report

80(1), pp. 163-170

Read Abstract (New Window)

Brent J. (2013)

Commentary on the abuse of metal chelation therapy in patients with autism spectrum disorders.

Journal of Medical Toxicology

9(4), pp. 370-372.

Read Abstract (New Window)

Britton J. W. (2002)

Antiepileptic drug withdrawal: Literature review.

Mayo Clinic Proceedings

77(12), pp. 1378-1388

Read Abstract (New Window)

Brodkin E. (1997)

Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.

Journal of Child and Adolescent Psychopharmacology

7(2), pp. 109-121

Read Abstract (New Window)

Brown M. J. et al. (2006)

Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005.

Pediatrics

118(2), e534-536

Read Full (New Window)

Caccia S. (2013)

Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Pediatric Drugs

15(3), pp. 217-233.

Read Abstract (New Window)

Cai Q. , Feng L. , Yap K. Z.

Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder.

Psychiatry and Clinical Neurosciences

Read Abstract (New Window)

Caldwell R. L. et al. (2012)

The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.

Research in Autism Spectrum Disorders

August, 22(4), pp. 277-283.

Read Abstract (New Window) Read Full (New Window)

Campbell M. et al. (1978)

A comparison of haloperidol and behavior therapy and their interaction in autistic children.

Journal of the American Academy of Child and Adolescent Psychiatry

17(4), pp. 640-655

Read Abstract (New Window)

Campbell M. et al. (1989)

Naltrexone in autistic children: an acute open dose range tolerance trial.

Journal of the American Academy of Child and Adolescent Psychiatry

28(2), pp. 200-206

Read Abstract (New Window)